20 November 2026
by Jeff Craven

Docket commenters call for flexibility in rare disease trial design and evidence, but question FDA’s RCT focus

FDA_Sign_260415_ALF.png
FDA headquarters in Silver Spring, MD. (credit: Ferdous Al-Faruque)

Comments to the US Food and Drug Administration (FDA) public docket on statistical considerations for study designs in rare disease clinical investigations supported the need for flexibility in trial design and evidence for rare diseases, but a few asked the agency to reconsider its focus on randomized controlled trials.

FDA convened a Rare Disease Innovation, Science, and Exploration (RISE) workshop in September 2026 that asked rare disease medical product developers, advocates, researchers, and others about statistical considerations in designing trials evaluating drugs and medical devices intended for rare diseases. The agency sought feedback on the content of that workshop as well as two pre-read documents on medical devices and drugs for rare diseases.

For drugs and biologics, FDA asked whether success criteria should be adjusted for rare disease trials, about the most feasible and acceptable way to integrate randomized designs, endpoint selection, and efficiency-enhancing strategies for rare disease studies. The medical device questions FDA posed included considerations for moving to a postmarket setting for class III devices, acceptable levels of evidence in single-arm device studies, use of external data sources for pivotal studies, and acceptable sources of prior information for studies including small patient populations.

Nearly all submitted comments concerned the questions about drugs and biologics for rare diseases. Commenters generally agreed that FDA should consider alternative approaches to trial design and evidence standards when conventional methods are deemed impractical, but raised concerns about FDA’s focus on randomized controlled trials during their September 2026 workshop.

Success criteria

The Biotechnology Innovation Organization (BIO) told FDA that the agency should consider alternative success criteria when conventional approaches are not feasible or appropriate, and to use a totality-of-evidence approach when evaluating findings in a clinical trial.

“In rare disease settings with small or heterogeneous populations, reliance on a single conventional significance threshold may not fully characterize treatment benefit and, in some circumstances, may make adequately powered trials infeasible,” the organization wrote.

BIO asked the agency to provide case studies that “support fit-for-purpose, context-specific application of these and other statistical approaches across diverse disease and evidentiary contexts.”

The Pharmaceutical Research and Manufacturers of America (PhRMA) also said that, while randomization maximizes precision and minimizes bias, the agency needs to “embrace scientifically rigorous, fit-for-purpose approaches that can generate precise and unbiased evidence and also reflect the feasibility and ethical realities of rare disease drug development.”

Otsuka Pharmaceutical Development & Commercialization called on FDA to focus on how “disease severity, unmet medical need, and feasibility constraints should be weighed when evaluating alternative evidentiary standards, as not all factors may warrant equal consideration in determining acceptable levels of statistical uncertainty in all cases.”

UCB said FDA should create a framework for discussing “prospectively discussing alternative success criteria with sponsors.”

More feasible randomized designs

Otsuka said they supported the use of approaches like unequal randomization, adaptive design, crossover or randomized withdrawal design, early stopping rules, seamless Phase 2 and Phase 3 studies, and external controls in randomized study designs.

“Additional clarity on FDA’s evidentiary expectations and regulatory acceptability would facilitate broader adoption in rare disease development,” they wrote.

BIO told FDA to use a fit-for-purpose approach when assessing the appropriateness of randomized concurrent controls, rather than a single approach across all rare disease programs.

“BIO encourages FDA to apply a fit-for-purpose, risk-based approach that supports innovative alternatives to randomized controls when appropriate, particularly where randomization is burdensome, ethically challenging, or infeasible in small populations, and to promote consistent, predictable evidentiary expectations for these approaches across FDA Centers,” they said.

UCB noted that randomized trials, where feasible, can be appropriate, but asked the agency to consider flexibility for rare disease populations.

“Patient and caregiver engagement should occur early in trial design to understand the acceptability of randomization, placebo, sham, or other control-arm exposure, trial duration, changes to treatment(s) patients receive prior to study enrollment, and opportunities to receive investigational treatment,” they said. “These considerations are likely to differ substantially depending on disease severity and progression, age of the population, availability of treatment options, expected duration of control-arm exposure, and the consequences of delaying treatment.”

PhRMA said the agency should support randomization in feasible and ethical scenarios where there is an increased likelihood that a trial participant will receive an effective treatment, where appropriate, “rather than designs that make an untreated control arm more tolerable.”

Endpoint selection

BIO asked FDA to promote endpoints that center patients and disease-contextualized principles that are “supported by natural history, patient experience, biomarkers, longitudinal data, and other fit-for-purpose evidence.”

“Early sponsor-FDA engagement and consistent regulatory feedback regarding endpoint acceptability can reduce avoidable development uncertainty while supporting endpoints that are both clinically meaningful and statistically credible,” they wrote.

Otsuka acknowledged the challenge of developing endpoints in rare diseases and encouraged FDA to take a similar approach as well as to consider “hierarchical composite endpoints, which may better capture clinically meaningful benefit across heterogeneous disease manifestations while maximizing information from small patient populations.”

UCB told FDA that a single endpoint may not adequately capture disease manifestations applicable across the patient population. “Requiring all participants to demonstrate benefit on the same manifestation may therefore fail to capture meaningful treatment benefit,” they wrote.

In their comment, PhRMA raised the issue of FDA sometimes rejecting a proposed endpoint “without offering clear rationale or providing meaningful direction on a route forward, short of conducting a pivotal trial at risk” as a challenge during rare disease drug development, and that sometimes how FDA considers an endpoint can change based on which Center or division is reviewing it.

“PhRMA encourages the Agency to be direct in its interactions with sponsors when it is departing from previous advice to minimize regulatory uncertainty,” they said.

Efficacy-enhancing strategies

BIO noted that statistical and trial design approaches can help address the data gaps commonly seen in small patient populations in rare disease studies.

“Depending on the disease and development program, promising strategies include Bayesian borrowing, external and hybrid controls, adaptive and sequential designs, covariate adjustment, longitudinal modeling, efficient use of continuous data, and master protocols or platform trials,” they explained.

UCB agreed that there should be a greater use of these designs and analytical methods to “enable more information to be obtained from the limited number of patients available for rare disease research.”

In terms of efficacy-enhancing strategies, PhRMA said the agency could also draw on lessons learned from regulatory science pilots, improve communication between sponsors and the agency, and increase staff training.

Other comments

The National Organization for Rare Disorders (NORD) raised concerns in their comment that the agency and outside speakers during the workshop had expressed a “strong preference” for randomized controlled trials (RCTs), which they say is at odds with FDA’s recent white paper on developing a fit-for-purpose framework for rare disease therapies.

Lilly raised a similar concern in their comment to FDA, noting that discussions in the September workshop “repeatedly returned to reasons a randomized concurrent control should be included rather than exploring how other innovative approaches could be made reliable.”

They stated that evidence that is fit-for-purpose is not “lower-standard evidence; it is designs and methods suited to the disease.” Lilly also encouraged FDA to use the agency’s fit-for-purpose framework for individual product reviews, and to apply a similar risk-based framework to the one used by the Center for Devices and Radiological Health (CDRH) for trials where randomized concurrent controls are not feasible or unethical.

NORD said FDA should start with “identifying the evidence necessary to establish treatment effectiveness, rather than treating the feasibility of an RCT as the threshold question.”

“Nonrandomized designs should be evaluated on their scientific merits and fitness for purpose, not presumed inferior solely because they lack randomization,” NORD said. “Scientific rigor must be met but must also be tailored to the disease and potential intervention.”

Public docket